Agoracom Blog Home

Posts Tagged ‘stocks’

#Ethereum set to become first #blockchain to settle $1 trillion in one year SPONSOR: Blockchain Foundry $BCFN.ca $HUT.ca $BITF.ca $GLXY.ca $HIVE.ca $VYGR.ca

Posted by AGORACOM-JC at 12:18 PM on Friday, October 23rd, 2020

SPONSOR POST:

http://blog.agoracom.com/wp-content/uploads/2020/10/blockchain-foundry-square.png

BCFN:CSE

  • A leading North American blockchain development firm
  • 2020 H1 Revenue Of ~$900,000
    • 187% Year Over Year Growth
    • Positive Net Income
  • Self sustaining consulting practice with growing pipeline and potential upside from product development and commercialization
  • Partnered with Binance, the largest digital asset trading platform in the world, to leverage the Syscoin platform.
  • A Blockchain company with Real Products, Real Customers, Real Revenues and Real Income
  • Blockchain Foundry is a “Blockchain 2.0” company that has survived and will thrive  

Hub On AGORACOM / Corporate Profile

Ethereum set to become first blockchain to settle $1 trillion in one year

  • According to crypto market data aggregator Messari, the 30-day rolling daily average for Ethereum transaction volume is currently $7 billion, with Bitcoin processing less than $3 billion.
  • If the current trend continues, Messari predicts Ethereum will become the first public blockchain to settle $1 trillion in transfers over a calendar year.

By: Samuel Haig

The third-quarter decentralized finance boom has resulted in the Ethereum (ETH) network processing more than twice the daily transaction volume of Bitcoin (BTC).

According to crypto market data aggregator Messari, the 30-day rolling daily average for Ethereum transaction volume is currently $7 billion, with Bitcoin processing less than $3 billion.

If the current trend continues, Messari predicts Ethereum will become the first public blockchain to settle $1 trillion in transfers over a calendar year.

Ethereum’s previous strongest calendar year relative to Bitcoin was 2018, when it processed half a billion in volume, which was 59% as much as Bitcoin’s $849 million that year.

Bitcoin is on-track for its second-strongest year behind 2018, projected to process $800 million. Yearly transaction value for Bitcoin and Ethereum: Messari

It’s not a straightforward comparison between the two blockchains, however. With the DeFi bubble largely taking place on top of Ethereum-powered smart contracts, the Ethereum network now processes the volume of an entire sector, while Bitcoin largely represents transfers of value denominated in BTC.

Messari’s Ryan Watkins attributes much of Ethereum’s volume spike to increased ERC-20 stablecoin volumes, with the majority of Tether (USDT) transactions now taking place on Ethereum and yield farming-driven demand pushing supply growth of more than 600% for MakerDAO’s Dai stablecoin.

Watkins also notes booming on-chain liquidity from decentralized exchanges, with Uniswap and Curve generating more than $20 billion in volume combined during September. DEXs now represent more than 13.6% of total exchange volumes.

However, Messari predicts “the next twelve months could come to define the platform wars” in crypto, noting Ethereum’s ongoing high fees as a problem that rival blockchains will seek to solve, alongside “the rise of parallel DeFi ecosystems.”

“Look for all would-be ETH Killers to continue to empty out their treasuries to build a parallel DeFi sector throughout the end of 2020 and beyond.”

In August, Chris Burniske, a partner at PlaceHolder Capital, asserted that Ethereum and Bitcoin are racing each other to reach the first $1 trillion market cap in crypto.

Source: https://cointelegraph.com/news/ethereum-set-to-become-first-blockchain-to-settle-1-trillion-in-one-year

Plant-Based Products Aren’t Just a Trend, They’re Here to Stay – Else Nutrition $BABY.ca $BABYF $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 11:40 AM on Friday, October 23rd, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Else Nutrition Brings Plant-Based Products to the Infant Nutrition Space

  • Demand for plant-based foods extends far beyond just burgers
  • One of the companies that has moved to fill a previously unserved segment of the plant-based food market is Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQX:BABYF), an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults.
  • The company’s flagship product is a non-soy, non-dairy plant-based infant nutrition formula. Else Nutrition celebrated its US product launch in August with products now available in retail stores and online.

NEW YORK, Oct. 23, 2020 – Over the past few years, plant-based meat and dairy substitutes have gone from a niche product to a major segment in the food industry. Now, these products are increasingly available just about everywhere you look in the food industry. Plant-based options are now available not just in your local grocery store but at your local pub and fast food joint. Plant-based products are now being offered by a wider range of brands from recently IPO’d startups to international giants. These products are also working their way into a wide range of subcategories in the food market, including infant nutrition and diet foods. In the wake of smash plant-based hits like Impossible Foods, companies like Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQX:BABYF) and Forum Merger II (NASDAQ:FMCI) are finding unserved niches in the market, while established food companies like Tyson Foods (NYSE:TSN), ConAgra Brands (NYSE:CAG), and Kellogg (NYSE:K) play catch-up.

Else Nutrition Brings Plant-Based Products to the Infant Nutrition Space

Demand for plant-based foods extends far beyond just burgers. One of the companies that has moved to fill a previously unserved segment of the plant-based food market is Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQX:BABYF), an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. The company’s flagship product is a non-soy, non-dairy plant-based infant nutrition formula. Else Nutrition celebrated its US product launch in August with products now available in retail stores and online.

On September 24, Else Nutrition announced that the company had made its products available to US consumers on Amazon.com. The move makes Else’s products available to more consumers than ever via the world’s largest e-commerce platform. Direct-to-consumer online sales are a cornerstone of Else’s go-to-market strategy, particularly as the ongoing global pandemic has driven up demand for products available via delivery. Additionally, Else Nutrition is also pushing to expand its presence in grocery and health food stores. The company announced on August 20 that it had hired a specialized broker to help bring their products to one of the US’s largest retail chains.

Else Nutrition announced on October 13 that Health and Happiness (H&H) International Holdings Limited, a global health and wellness company and a leading infant nutrition player in China, had increased its investment in the company by C$4.0 million. The private placement, which was previously announced on September 15, now totals C$25.7 million. Else Nutrition plans to use the funds to accelerate and increase its production and supply capabilities, marketing activities, and product development.

Companies Move into the Plant-Based Foods Market

Tyson Foods (NYSE:TSN), the largest meat company in the United States, announced in June that it would be moving into the plant-based meat alternative market. The company announced its new Raised & Rooted brand, which will sell plant-based and mixed meat/plant products. Tyson Foods, with its already massive consumer reach, says it expects plant-based foods to be a billion-dollar business for the company.

ConAgra Brands (NYSE:CAG), the parent company for brands like Orville Redenbacher, Hunts, and Duncan Hines, has been selling meat-free products through its Gardein brand since 2009, but as plant-based meat substitutes have surged in the market, the company is updating its offerings. On September 23, ConAgra announced a line of Gardein soups featuring plant-based meat alternatives.

Kellogg (NYSE:K) got in on the plant-based trend with its Incogmeato line of products. The company is focusing on products aimed at families and young children. To that end, Kellogg announced on September 17 that the company would be partnering with Disney for its latest plant-based offering, Mickey Mouse-branded “Chick’n” Nuggets.

On October 15, holding company Forum Merger II (NASDAQ:FMCI) announced a partnership with plant-based food company Ittella International to form the Tattooed Chef brand. Tattooed Chef will focus on a wide range of meatless foods, some of which will include plant-based meat alternatives. 

Plant-based alternatives to meat are the biggest trend in the food industry in years, and the marketplace is filling up fast. Companies like Else Nutrition are positioning themselves within specific, previously unserved segments of the food industry to ensure that they can become the main plant-based players in that space.

For more information about Else Nutrition, click here.

DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. MSC owns and operates Streetsignals.com.  References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Else Nutrition Holdings.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

Media Contact:
FN Media Group, LLC
[email protected]
+1(561)325-8757

Innocan Pharma $INNO.ca Announces the Publication of Two Studies Supporting Its CLX Therapy for COVID-19 Infected Lung Cells $IN.ca $AXIM $LABS $CRDL.ca $TBP.ca

Posted by AGORACOM-JC at 7:35 AM on Friday, October 23rd, 2020
Innocan-Blog
  • Announced the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19
  • The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020
  • study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors
  • The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020
  • Demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms

Herzliya, Israel and Calgary, Alberta–(October 23, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce the recent publication of two scientific articles supporting Innocan’s approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19. The first paper entitled, “Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients” published in the Journal of Stem Cell Research & Therapy on October 15, 2020 outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19. Specifically, the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

The second paper entitled, “Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome” published in the Journal of Cellular and Molecular Medicine on October 15, 2020, demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.

Innocan Israel, a wholly owned subsidiary of the Company, together with Tel Aviv University Prof. Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.

Through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus’s direct damage and its cytokine storm. This product is planned to act as a “guided missile” to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.

Prof. Offen added: “The recent publications which support our unique approach is exciting. The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction. We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment”.

About Innocan

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Israel and Ramot at Tel Aviv University, are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Coronavirus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz Head of the Laboratory of Membrane and Liposome Research of The Hebrew University of Jerusalem, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Innocan Pharma Corporation
Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable

$HPQ.ca NANO Receives First Order for Spherical Nano Silicon Material from Major Automobile Manufacturer $EFL.ca $EGT.ca $ENPH $PYR.ca

Posted by AGORACOM-JC at 3:10 PM on Thursday, October 22nd, 2020
  • Announced today that the major automobile manufacturer that demonstrated an interest in the Spherical Nano Silicon powders to be produced by the PUREVAP TM Nano Silicon Reactor (“NSiR ”) ( Sept. 30 2020 release ) has submitted to HPQ NANO a formal Purchase Order for the material
  • This represents HPQ NANO first ever nanopowders order 
  • Manufacturer is well aware that HPQ NANO will only fulfill this first order in December 2020 and, as such, this order is simply a way for them to guarantee to be first in queue for the material
  • The automobile manufacture’s name shall remain anonymous for competitive and confidential reasons

MONTREAL, Oct. 22, 2020 — Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or “the Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC : URAGF ) through its wholly – owned subsidiary, HPQ Nano Silicon Powders inc (“HPQ NANO”), is pleased to announce today that the major automobile manufacturer that demonstrated an interest in the Spherical Nano Silicon powders to be produced by the PUREVAP TM Nano Silicon Reactor (“NSiR ”) ( Sept. 30 2020 release ) has submitted to HPQ NANO a formal Purchase Order for the material. This represent HPQ NANO first ever nanopowders order.   The manufacturer is well aware that HPQ NANO will only fulfill this first order in December 2020 and, as such, this order is simply a way for them to guarantee to be first in queue for the material.   The automobile manufacture’s name shall remain anonymous for competitive and confidential reasons.

INTEREST IN OUR SPHERICAL NANO SILICON POWDERS IS JUST STARTING!

HPQ NANO is looking forward to the December 2020 start of the Gen1 PUREVAP TM NSiR reactor in order to start delivering material as we work to keep up with the expected strong interest in our Nano Silicon products.

“This is indeed significant news. To have piqued the interest of a major industrial player so early on, and to the point where they have sent us a formal purchase order for product , before production , just to insure their first mover position speaks volumes about where we are and what we are doing ,” said Bernard Tourillon, President & CEO of HPQ Silicon and HPQ NANO . “ This validate our strategic decision to enter this space . W e are extremely proud as a Company to be at this table at this unique time . However, I must caution investors that although this order signal s interest in our unique products, we are still at the very preliminary stages and there is no guarantee that anything of commercial value will materialize from these efforts. It does however demonstrate the potential for new and exciting advances by HPQ NANO in the silicon battery space.”

This is a remarkable achievement , and one which clearly underscores both the significant underlying interest in such powders and , as such, the potential impact this product offering could have o n the industry.” said P. Peter Pascali CEO and Chairman of PyroGenesis Canada Inc. As technology provider we would be the first to say that nothing is guaranteed. In every new application there will always be challenges along the way, both anticipated and unanticipated. With that in mind, we are happy to note that at this point in time we see nothing that should prevent us from successfully producing the desired powders using PUREVAP TM Nano Silicon Reactor .

About Silicon

Silicon (Si), also known as silicon metal, is one of today’s strategic materials needed to fulfil the Renewable Energy Revolution (“RER”) and the decarbonization of the economy presently under way. Silicon does not exist in its pure state; it must be extracted from quartz (SiO 2 ), in what has historically been a capital and energy intensive process.

About HPQ Silicon

HPQ Silicon Resources Inc. ( TSX-V: HPQ ) is a Canadian producer of Innovative Silicon Solutions, based in Montreal, building a portfolio of unique high value specialty silicon products needed for the coming RER.

Working with PyroGenesis Canada Inc. (TSX-V: PYR) , a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:

  • The PUREVAP TM “Quartz Reduction Reactors” (QRR) , an innovative process (patent pending), which will permit the one step transformation of quartz (SiO 2 ) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential ;
    • HPQ believes it will become the lowest cost (Capex and Opex) producer of silicon (Si) and high purity silicon metal (3N – 4N Si);
  • Through its 100% owned subsidiary HPQ NANO Silicon Powders Inc, the PUREVAP TM Nano Silicon Reactor (NSiR ) , a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires;
    • HPQ believes it can also become the lowest cost manufacturer of spherical Si nanopowders and silicon-based composites needed by manufacturers of next-generation lithium-ion batteries ;
    • During the coming months, spherical Si nanopowders and nanowires silicon-based composite samples requested by industry participants and research institutions’ will be produced using PUREVAP TM SiNR .

HPQ is also working with industry leader Apollon Solar of France to:

  • Use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders;
    • The collaboration will allow HPQ to become the lowest cost producer of porous silicon wafers for all-solid -state batteries and porous silicon powders for Li-ion batteries;
    • Develop the hydrogen generation potential of Silicon nanopowders for usage with the Gennao TM system;
    • Commercialize, exclusively in Canada, and non-exclusive in the U.S.A., the Gennao TM H2 system and the chemical powders required for the hydrolysis production of Hydrogen (“H2”).

This News Release is available on the company’s CEO Verified Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

Disclaimers:

The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact

Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011
Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239
http://www.hpqsilicon.com Email: [email protected]

PK Beans $BEAN.ca Ends Fiscal Year with 42% Increase in Revenue for Month of September; Completes Shares for Debt Transaction

Posted by AGORACOM-JC at 9:10 AM on Thursday, October 22nd, 2020
Pk beans
  • Reports significant increase in sales year over year for September 2020
  • Company saw a 42% increase in sales for the month when compared to September 2019, coinciding with a 68% increase in web traffic and an 80% increase in orders
  • Also reports that 71% of the months’ sales is a result of direct traffic; indicating customers actively seeking to shop PK Beans directly

Vancouver, British Columbia–(October 22, 2020) – Peekaboo Beans Inc. (CSE: BEAN) (OTCQB: PBBSF) (“PK Beans” or the “Company”), a responsible and innovative children’s apparel brand, is pleased to report significant increase in sales year over year for September 2020. The Company saw a 42% increase in sales for the month when compared to September 2019, coinciding with a 68% increase in web traffic and an 80% increase in orders. The Company also reports that 71% of the months’ sales is a result of direct traffic; indicating customers actively seeking to shop PK Beans directly.

These numbers are further indicators of PK Beans recent launch of Fall 2020 Styles, their first collection launched with their ‘PK Beans’ rebrand. These styles for baby, boy and girl have proven to be a strong collection for the company.

Additionally, PK Beans would like to announce that it has entered into debt settlement agreements with certain parties (the “Creditors“) to settle an aggregate C$98,916.65 in debt (the “Debt“). In settlement of the Debt, the Company will issue an aggregate of 1,978,333 common shares in the capital of the Company (the “Debt Shares“) at a deemed price of C$0.05 per Debt Share (the “Debt Settlement“).

The Creditors include an officer who will receive 770,000 common shares in settlement of accounting services and an officer who will receive 1,020,833 common shares in settlement of accrued payroll. The issuance of Shares to these officers constitutes a “related party transaction” as this term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions (“MI 61-101”). The Company is relying on the exemption from valuation requirement and minority approval pursuant to subsection 5.5(a) and 5.7(a) of MI 61-101, respectively, as the securities do not represent more than 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The participation by the director in the Shares for Debt Settlement was approved by directors of the Company who are independent in connection with such transactions.

All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

Closing of the Shares for Debt Settlement is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the Canadian Securities Exchange.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Peekaboo Beans Inc.

PK Beans is an innovative children’s apparel brand with a focus on environmentally responsible clothes that are intentionally designed to inspire play. Through an omni-channel approach, Peekaboo Beans engages sellers through social platforms, including Instagram and Facebook, as well as online retailers, to maximize revenue and build brand loyalty. The Company works to promote a playful lifestyle for children by designing comfortable clothes that are built to last.

To learn more about PK Beans, visit: www.pkbeans.com.

On behalf of the Board of Directors,
Peekaboo Beans Inc.

Ms. Traci Costa, President and CEO
(604) 279-2326

For more information, please contact the Company at:
[email protected]
1-604-279-2326

Reader Advisory

This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO US NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

FansUnite Entertainment $FANS.ca $FUNFF Expands Product Offering into European Online Casino Aggregator $DKNG $PENN $GAN $BRAG.ca $FDM.ca

Posted by AGORACOM-JC at 7:18 AM on Thursday, October 22nd, 2020
  • Askott Games has signed with a leading online casino games aggregator to distribute its proprietary Random Number Generated (RNG) games to online casinos and sportsbooks in the European market
  • Askott Games will see their RNG games available to over 120 online casino websites
  • Besides hosting the games on its B2B offering, the Chameleon Gaming Platform, Askott Games will sign agreements with existing casino game aggregators to make the games available to thousands of online casinos and sportsbooks worldwide

Vancouver, British Columbia and Sliema, Malta–(October 22, 2020) –  FansUnite Entertainment Inc. (CSE: FANS) (OTC Pink: FUNFF) (“FansUnite” or the “Company”), a technology company providing leading online gaming solutions, is pleased to announce Askott Games has signed with a leading online casino games aggregator to distribute its proprietary Random Number Generated (RNG) games to online casinos and sportsbooks in the European market.

The first casino game aggregator to publish the Askott Games content will be The Ear Platform. The Ear is a European-focused aggregator that will give Askott Games access to more than 120 online gaming sites they are integrated with.

FansUnite has produced unique esports and video game-themed RNG/casino games under the Askott Games brand, which are ready to be launched to the market. Besides hosting the games on its B2B offering, the Chameleon Gaming Platform, Askott Games will sign agreements with existing casino game aggregators to make the games available to thousands of online casinos and sportsbooks worldwide. Game aggregators compile the best casino games they can find and offer them to online casinos and sportsbooks through a single integration. Given that the arrangements are on a revenue share basis, Askott Games will receive a share of the net gaming revenue every time one of their games is played.

“When we started Askott Games we knew that online casinos were looking for ways to reach and engage with younger customers that were not interested in traditional casino offerings,” said Scott Burton, CEO of FansUnite Entertainment. “The positive response we have received for our internally produced esports and video game-themed RNG games validates this thesis.”

“This integration with Ear will provide more exposure to our games and will enable us to market to over 120 websites and thousands of end customers. This deal and the ones thereafter, give us the ability to sell our games through the networks aggregators have built and provide us the ability to quickly scale while producing a steady stream of recurring revenue to our overall business.”

Andrei Siomela, Commercial Director of The Ear Platform, added, “We pride ourselves on having the best casino offerings available to our customers. Currently, we provide over 120 iGaming sites throughout Europe with casino games developed by tier 1 game providers. With the games that Askott is producing, we can offer games specifically designed for the most desirable audience, 18-30-year-olds, to our partners. Our customers are looking for solutions that appeal the most to this demographic. We can’t wait to have Askott Games incorporated into our platform, and we have been very excited to see the pipeline of games that the Askott team has in development.”

Askott Games is currently completing its fourth game with plans for over ten within the next 12 months. With this announcement, FansUnite will also be launching the dedicated Askott Games (askott.games) site and begin business development.

About FansUnite Entertainment Inc.

FansUnite is a global sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. FansUnite has produced a one of a kind complete iGaming platform, Chameleon Gaming Platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform includes products for pre-match betting, in-play betting, daily fantasy, content and a certified RNG to produce casino style chance games. The platform operates multiple B2C brands and B2B software for the online gambling industry. FansUnite also looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

For further information, please contact:

Prit Singh Investor Relations at FansUnite
[email protected]
(905) 510-7636

Scott Burton Chief Executive Officer of FansUnite
[email protected]

Darius Eghdami President of FansUnite
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDERS HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING STATEMENTS: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or similar expressions to be uncertain and forward-looking. Forward-looking statements may include, without limitation, statements relating to future outlook and anticipated events such as: agreements to be entered into with online casino games aggregators; the distribution of Askott Games’ ‎RNG games to online casinos and sportsbooks; the markets in which RNG games are to be distributed; the ‎timing of launch and distribution of Askott Games’ esports and RNG games to the markets; the offering, ‎integration and distribution of Askott Games’ esports and RNG games by The Ear and other game ‎aggregators; revenues to be received by Askott Games in connection with their esports and RNG games; ‎Askott Games’ plans to develop and release games over the next 12 months; the launch of the Askott ‎Games website; commencement of Askott Games’ business development plans; expectations of the ‎Company with respect to the interest of aggregators in Askott Games’ esports and RNG games; market ‎exposure to and interest in Askott Games’ esports and RNG games resulting from the integration of its ‎gaming platform into The Ear; the ability of the Company to scale quickly and produce high recurring ‎revenues; Askott Games becoming the Company’s largest source of revenue in 2021;‎ the Company’s ability to become a leading technology platform and a leader in the global I-gaming market, and to serve the gaming market; the potential growth of the Company and the gaming market; the increased number of betting options; the ability of the Company to scale its B2B arm and maintain its B2C platforms; the Company’s unique portfolio of assets; and discussion of future plans, projections, objectives, estimates and forecasts and the timing related thereto. Forward-looking statements are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of FansUnite to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Additional information regarding the risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Non-Offering Prospectus dated March 27, 2020 filed on its issuer profile on SEDAR at www.sedar.com and risks related to global pandemics, including the novel coronavirus (COVID-19) global health pandemic, and the spread of other viruses or pathogens and influence of macroeconomic developments. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The forward-looking statements in this news release are made as of the date of this release. FansUnite disclaims and does not undertake to update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

#Amazon $AMZN Web Services And Loop Insights $MTRX.ca Partner To Showcase Loop Venue Tracing Solution Via Joint Webcast To Global Audience $AT.ca $QTRH.ca $SNSR $BSQR $PTS.ca

Posted by AGORACOM-JC at 7:12 AM on Thursday, October 22nd, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png
  • Amazon Web Services (AWS) and Loop Insights will be hosting an interactive webinar to showcase the Company ‘ s Venue Tracing Solution to a global audience on October 29th .
  • Amazon Web Services (AWS) Principal Solutions Architect Mike Apted and Loop Insights CEO Rob Anson will be co-hosting the event
  • Will provide invitees with a first hand and interactive experience of Loop ‘ s End-To-End Venue Tracing Platform
  • Will be an open invitation to all AWS and Loop partners from around the world from industries including but not limited to Airlines, Venue Owners, Sports & Entertainment, Telecom, and Government to learn about the technical, security, privacy, and commercial aspects of Loop ‘ s Venue Tracing Platform

VANCOUVER, BC , Oct. 22, 2020 – Loop Insights Inc. (MTRX: TSXV) (RACMF: OTCQB) (the ” Company” or ” Loop”), a provider of contactless solutions and artificial intelligence ( ” AI”) to drive real-time insights, enhanced customer engagement and automated contact tracing to the brick and mortar space, is pleased to announce that Amazon Web Services (AWS) and Loop Insights will be hosting an interactive webinar to showcase the Company ‘ s Venue Tracing Solution to a global audience on October 29th .

THE EVENT

Amazon Web Services (AWS) Principal Solutions Architect Mike Apted and Loop Insights CEO Rob Anson will be co-hosting the event, which will provide invitees with a first hand and interactive experience of Loop ‘ s End-To-End Venue Tracing Platform.

This will be an open invitation to all AWS and Loop partners from around the world from industries including but not limited to Airlines, Venue Owners, Sports & Entertainment, Telecom, and Government to learn about the technical, security, privacy, and commercial aspects of Loop ‘ s Venue Tracing Platform.

EVENT BUILDS ON AMAZON APPOINTMENT OF LOOP INSIGHTS TO PREFERRED PARTNER NETWORK INCLUDING 90% OF FORTUNE 100

On June 8, 2020 , Loop was accepted into Amazon Web Services Partner Network (APN), the global partner program for leading technology businesses from which more than 90% of Fortune 100 companies source their solutions and services.

Some of the benefits of the APN include networking opportunities to gain access to hundreds of ongoing AWS portfolios, as well as co-development projects and continued AWS resources that support product development, marketing, and sales.

With many if not most AWS business accounts facing significant economic challenges requiring solutions that can safely and effectively re-start normalized operations and financial recovery, Loop ‘ s APN status in conjunction with AWS position as a trusted source of solutions is expected to create both significant participation in the webcast and interested in Loop ‘ s Venue Tracing Platform.

Loop Insights CEO Rob Anson stated, ” The COVID-19 Pandemic has impacted the safety and financial security of people, businesses and governments across the planet. These entities look for solutions that can protect people, instill confidence, and get their economies open once again. AWS has provided us with the great technical support necessary to develop our Contactless Venue Tracing Platform and are now taking our APN Partner status a giant step forward by introducing our made in Canada solution to their incredible global audience. We look forward to giving all invitees an incredible demonstration.”

LOOP INSIGHT VENUE TRACING PLATFORM IS BUILT AND SUPPORTED BY AWS CLOUD INFRASTRUCTURE

Loop ‘ s Venue Tracing platform is clearly gaining recognition and third-party validation, including implementations with:

Major Las Vegas Hospitality Chains
University of Houston ;
NCAA #VegasBubble; and
Most recently being accepted into the TELUS IoT Marketplace as ” one of the most advanced IoT business solutions in the world”

RECENTLY ANNOUNCED TRAVEL BUBBLE SOLUTION TO HELP SAVE $3.3 TRILLION IN POTENTIAL LOSSES FOR GLOBAL TOURISM

On October 19 , Loop announced a travel bubble solution to provide end-to-end protection for travelers and the international travel industry.

Without a solution to replace the drastic travel measures currently in place around the world, the United Nations Conference on Trade and Development (UNCTAD) reported that COVID-19 might cost the world tourism sector losses of US$ 3.3 trillion .

Specifically, as of today, travel restrictions by country are as follows:

58 countries are completely closed
124 countries are partially open with MANDATORY quarantine upon arrival
(Source – https://www.ca.kayak.com/travel-restrictions )

The Travel Bubble solution is built on the following pillars:

Venue tracing
Frequent testing with rapid results
Real-time reporting to ensure the travel bubble provides end-to-end protection

It will be showcased in the presentation to serve as an example of Loop ‘ s ability to protect and re-open businesses, industries, and governments worldwide, including hospitality, education, sports & entertainment, and more.

Sign up for Amazon Web Services And Loop Insights Venue Tracing webcast here https://www.loopinsights.ai/webinar-sign-up/

This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/LoopInsights

About Loop Insights : Loop Insights Inc. is a Vancouver -based Internet of Things ( ” IoT”) technology company that delivers transformative artificial intelligence ( ” AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada , the US, the UK, Latin America , Australia , Japan , and Indonesia. Loop s products and services are backed by Amazon s Partner Network.

For more information, please contact:
 
Loop Insights Inc.LOOP Website : www.loopinsights.ai
Rob Anson, CEOFacebook: @ LoopInsights
T : +1 877-754-5336 Ext. 4Twitter: @ LoopInsights
E : [email protected]LinkedIn: @LoopInsights

Forward-Looking Statements/Information:

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Empower Clinics $CBDT.ca Enters Canadian Market with Proposed Acquisition That Includes 6 Clinics and Incentives to Open Additional 30 Clinics and Announces Private Placement of Up to $1.1 Million $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 5:14 PM on Wednesday, October 21st, 2020
  • Announced it has entered into a non-binding term sheet to acquire the businesses of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health“).
  • Momentum Health operates a network of medical clinics with a comprehensive team of physicians and therapists who apply a holistic and hands on approach working with patients to unlock potential well-being.
  • 6 clinics in greater Toronto area with plans to expand
  • Closing will be conditional upon, amongst other customary items listed below, Empower completing a debt or equity financing to raise minimum gross proceeds of $750,000 CAD
  • To this end, the Company has entered into an agreement with Mackie Research Capital Corporation in connection with a best efforts, private placement for gross proceeds of up to $1,100,000, the details of which are outlined below
  • The private placement is scheduled to close on or about the week of November 2, 2020.

Acquisition Expands Company’s North American Footprint And Strengthens Vertical Integration From Patients To Laboratory

VANCOUVER, BC / October 21, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower“), a vertically integrated health and wellness company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and a world-class medical diagnostics laboratory, is pleased to announce it has entered into a non-binding term sheet to acquire the businesses of Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc dba Atkinson, and Momentum Health Inc. collectively (“Momentum Health“).

Closing will be conditional upon, amongst other customary items listed below, Empower completing a debt or equity financing to raise minimum gross proceeds of $750,000 CAD. To this end, the Company has entered into an agreement with Mackie Research Capital Corporation in connection with a best efforts, private placement for gross proceeds of up to $1,100,000, the details of which are outlined below. The private placement is scheduled to close on or about the week of November 2, 2020.

Closing of the acquisition is expected to occur on or about November 10, 2020.

6 CLINICS IN GREATER TORONTO AREA WITH PLANS TO EXPAND MODEL ACROSS CANADA

Momentum Health operates a network of medical clinics with a comprehensive team of physicians and therapists who apply a holistic and hands on approach working with patients to unlock potential well-being. Key services include Physiotherapy, Chiropractic, Massage Therapy, Traditional Chinese Medicine, Athletic Therapy and others.

The proposed acquisition will include the acquisition of two standalone wellness clinics and four new co-located clinics in the Greater Toronto area of Ontario, Canada. Moreover, the proposed acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.

Steven McAuley, Chairman and CEO of Empower Clinics stated, “The acquisition of Momentum Health is expected to advance the direction and growth prospects for Empower overall,” said Steven McAuley, Empowers Chairman & CEO. “As we continue to position Empower as an integrated healthcare company, bringing alternative care together with primary care facilities enables us to deploy a better healthcare model, based on progressive technology and in-person care. Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empowers clinic footprint across Canada is another important step toward our growth objectives.”

Momentum Health Co-Founder Dr. Rabinowitz commented “Our core values of professionalism, corporate responsibility and community health fall directly in line with Empower. We are extremely excited to collaborate with this tremendous organization to provide reliable and trusted healthcare for communities across Canada.”

Momentum Health Co-Founder Dr. Tsimerman commented “Momentum Health has always stood on the foundations of providing an unparalleled patient experience and bridging the gap between the conventional medical system and paramedical services.”

PROPOSED TERMS OF ACQUISITION

Under the proposed terms, the Company will pay $275,000 CAD cash at closing and a $75,000 CAD performance holdback, for an aggregate cash payment of $350,000 CAD. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman common shares in the capital of Empower (“Shares“) having an aggregate value of $250,000 CAD and, subject to the satisfaction of defined performance metrics, additional Shares having an aggregate value of $250,000 CAD, which will vest in quarterly installments over 24 months following the closing. All Share consideration is expected to be based on a deemed price per Share equal to the 10-day volume weighted average closing price per Share on the Canadian Securities Exchange (the “CSE“) for the period ending on the last business day prior to the closing.

PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS

The proposed acquisition also includes long-term performance incentives that upon achieving the opening of:

Ten (10) new clinic locations (“Milestone One”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable option (the “Share Option“) to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

Twenty (20) new clinic locations (“Milestone Two”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable Share Option to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

Thirty (30) new clinic locations (“Milestone Three”) the issuance to the Vendors subject to terms and conditions as set out in the Stock Option Plan, an irrevocable Share Option to purchase at any time or from time to time on or before the Expiration Date, 1,250,000 Shares of the Corporation.

All issuances will be at a deemed price per Share equal to the 10-day volume weighted average closing price per Share on the CSE for the period ending on the last business day prior to the achievement of Milestone One, Two or Three.

ADDITIONAL DETAILS

The proposed consideration assumes a debt free transaction and will be adjusted accordingly for any level of debt assumed by the Company, directly or indirectly. The transaction is expected to be structured on a tax efficient basis, and otherwise in accordance with the requirements of requisite securities laws and the policies of the CSE.

Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman, to lead the proposed Canadian clinic expansion strategy.

Completion of the transaction includes Momentum Health interests in certain affiliates and will be subject to various conditions, including entry into a definitive agreement, completion of due diligence, and receipt of all required shareholder, manager, third party and regulatory approvals, including approval of the CSE.

PRIVATE PLACEMENT

The Company is also pleased to announce that it has entered into an agreement with Mackie Research Capital Corporation, as sole agent and sole bookrunner (the “Agent“), in connection with a best efforts, private placement of units of the Company (the “Units“) at a price of $0.05 per Unit (the “Offering Price“) for gross proceeds of up to $1,100,000 (the “Offering“).

Each Unit will be comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant shall be exercisable to acquire one Common Share (a “Warrant Share“) at a price of $0.12 per Warrant Share for a period of 24 months from the closing of the Offering.

The Agent will have an option (the “Agent’s Option“) to offer for sale up to an additional 15% of the number of Units sold in the Offering at the Offering Price, which Agent’s Option is exercisable, in whole or in part, at any time up to 48 hours prior to the closing of the Offering.

The Company intends to use the proceeds raised under the Offering to support the development of clinics through clinic acquisitions, lab testing services, sales and marketing, for general working capital purposes.

The securities to be issued under the Offering will be offered by way of private placement in each of the provinces of Canada, and such other jurisdictions as may be determined by the Company, in each case, pursuant to applicable exemptions from the prospectus requirements under applicable securities laws.

The Offering is scheduled to close on or about the week of November 2, 2020, or such date as agreed upon between the Company and Agent (the “Closing“) and Closing of the Offering may occur in multiple tranches, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Canadian Securities Exchange. The Units to be issued under the Offering will have a hold period of four months and one day from Closing.

In connection with the Offering, the Agent will receive an aggregate cash fee equal to 8.0% of the gross proceeds from the Offering, including in respect of any exercise of the Agent’s Option. In addition, the Company will grant the Agent, on date of Closing, non-transferable compensation options (the “Compensation Options“) equal to 8.0% of the total number of Units sold under the Offering (including in respect of any exercise of the Agent’s Option). Each Compensation Option will entitle the holder thereof to purchase one Unit at an exercise price equal to the Offering Price for a period of 24 months following the Closing.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Primo Nutraceuticals Inc. $PRMO.ca signs a Memorandum of Understanding for Exclusive Rights to Sell Rapid (Colloidal Gold Method) COVID-19 Test Kits in Canada $MRS.ca $FTI.ca $MMM $HON $MSA

Posted by AGORACOM-JC at 8:07 AM on Wednesday, October 21st, 2020
  • Signed of a Memorandum of Understanding with Neo-Nostics(Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit).
  • Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020
  • Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.

VANCOUVER, British Columbia, Oct. 21, 2020 – PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (” PRIMO ” or the “Company”) announces the signing of a Memorandum of Understanding (MOU) with Neo-Nostics(Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China (“Neo-Nostics”) as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit).

The Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020. Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.

The Neo-Nostics2019-nCoV IgG/IgM Rapid Testing Kit is currently registered with the FDA. Primo will be submitting the application for approval to Health Canada immediately. Neo-Nostics ™ has committed to supporting Primo’s efforts to obtain and maintain all necessary certifications and approvals for the sale and marketing of the Test Kits in Canada by granting access to all necessary documentation and clinical studies concerning the Test Kits.

Follow the link for a video demonstration: http://www.neo-nostics.com/skin/images/mp40.mp4

About the Neo-NosticsRapid Test Kits

The Neo-Nostics 2019-nCoV Antibody Detection Reagent Kit (Colloidal Gold Method) has the advantage of rapidity, convenience, high accuracy, and can make up for the shortcomings of professional requirements, time consumption and low positive detection rate of PCR nucleic acid detection, and can be used as an important supplementary detection method for the diagnosis of coronal pneumonia.

Through detection and calculation, it is found that the comprehensive accuracy rate of the Neo-Nostics2019-nCoV IgM Detection Reagent is higher than 95%.

During the worst period of the epidemic in China, the reagent kit was donated to hospitals and the CDC in the most severely infected areas of Hubei for clinical auxiliary diagnosis. At present, the verification reports made by three clinical units prove that the positive detection rate of clinically confirmed cases has reached 92%, which has exceeded the general detection effect. Not only negative or positive results can be detected, but also the early, middle and or recovery period of virus infection can be distinguished by the positive strength of IgM or IgG.
Source: Clinical study report conducted by the Institute of Virology, in the capital city of Hubei, China and The Chinese Academy of Sciences in Beijing, China.

DISCLAIMER: “The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time”.

Clinical Applications of Reagents

This reagent has been used by professionals in China since February 2020 in an area that was the hardest hit and impacted most severely by COVID-19, in the form of clinical auxiliary diagnosis.

The reagent kit was clinically verified by several professionals, hospitals, and universities respectively, and corresponding reports were used as reference.

At present, Iran, Italy, the United States, and other red zones have already adopted it . Neo- N osticshas CE declaration of conformity, local records of European Authorized Representative and FDA records in the United States.

View the FDA records here: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=669386&lpcd=QKO

Advantages of the Colloidal Gold Method

1. Quick – 10 minute results.

2. Simple – The detection results can be determined by the naked eye.

3. Sampling – Only fingertip blood or venous blood is required for detection.

4. It is suitable for clinical auxiliary diagnosis.

About the COVID-19 Detection Kit Market

According to a new report by Grand View Research, Inc., The global COVID-19 detection kits market size is projected to reach USD 4.63 billion by 2027 . The COVID-19 pandemic has posed several challenges to the global healthcare systems. As a result, companies are ramping up their production process to meet the demand or kits and reagents as well as at-home tests, thereby driving the market revenue. https://www.grandviewresearch.com/industry-analysis/covid-19-detection-kits-market?utm_source=prnewswire&utm_medium=referral&utm_campaign=hc_15-sep-20&utm_term=covid-19-detection-kits-market&utm_content=rd

Mr. Joey Zhou, CEO of Neo-Nostics(Suzhou) Bio-Engineering Co. Ltd. Comments:

“Penetrating the Canadian market with our advanced and highly effective test kit will be a great milestone for our company as well as for the fight against theCOVID-19 virus. We are pleased to be partnering with Primo Nutraceuticals and their team”

Richard Cindric, CEO of Primo Comments:

We are looking forward to working with Neo-Nosticsto provide a premium quality product. We anticipate the relationship to grow and look forward to updating our shareholders with our future milestones.” It is important to note that receiving the MDEL license from Health Canada has opened up a plethora of opportunities like this one which will result in revenue in the immediate short term for Primo and its shareholders.”

About Neo-Nostics(Suzhou) Bioengineering Co. Ltd.

Neo-Nostics ™ (Suzhou) Bioengineering Co., Ltd. which was established in 2015, is a professional company specialized in researching, developing, manufacturing, and distributing advanced medical instruments and in-vitro medical diagnostic products. Their products are usually used for fertility tests, infectious diseases tests, drugs of abuse tests, alcohol saliva tests, urinalysis reagent strips, cardiac marker tests, tumor marker tests, food and safety tests and animal disease tests.

To learn more about Neo-Nosticsplease visit: http://www.neo-nostics.com/en/

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the company; specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal
President and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Loop Insights $MTRX.ca Invited to Present to Fortune 500 Executives at #Shoptalk 2020, One of the World’s Largest Retail Conferences $AT.ca $QTRH.ca $SNSR $BSQR $PTS.ca

Posted by AGORACOM-JC at 7:19 AM on Wednesday, October 21st, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png
  • Senior Vice President (SVP) of Business Development Mike Canevaro has been selected to lead a roundtable discussion at Shoptalk 2020 regarding the future of the brick and mortar retail space
  • Shoptalk is one of the world’s largest annual retail conferences where brands and consumers in the retail and eCommerce industry gather to network, collaborate, and learn
  • The three-day virtual conference is being held October 20th until Thursday, October 22 nd , 2020

VANCOUVER, British Columbia, Oct. 21, 2020 — Loop Insights Inc. (MTRX:TSXV OTCQB:RACMF) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (AI) to drive real-time insights, enhance customer engagement, and automate contact tracing to the brick and mortar space, is pleased to announce that Loop Insights Senior Vice President (SVP) of Business Development Mike Canevaro has been selected to lead a roundtable discussion at Shoptalk 2020 regarding the future of the brick and mortar retail space.

LOOP MEETING WITH FORTUNE 500 REPRESENTATIVES

Shoptalk is one of the world’s largest annual retail conferences where brands and consumers in the retail and eCommerce industry gather to network, collaborate, and learn. The three-day virtual conference is being held October 20th until Thursday, October 22 nd , 2020.

ShopTalk 2020 attendees include Fortune 500 executives from across the retail space, including Walmart, VISA, Nike and Carnival Corporation.

In addition to leading a roundtable, Canevaro is scheduled to meet with representatives from across the retail landscape, including Fortune 500 companies.

LOOP TO LEAD PRESENTATION ON TRANSFORMATION OF BRICK AND MORTAR SPACE THROUGH CONTACTLESS ENGAGEMENT

ShopTalk is designed to connect Fortune 500 companies, including major brick and mortar retailers, with the platforms and technologies capable of transforming the current retail landscape. Loop’s contactless engagement and insights platform allows Fortune 500 brick and mortar retailers to leverage the power of artificial intelligence to elevate the customer experience, and increase basket size and spend through personalized offers that will allow them to rival online retail giants.

Loop Insights SVP Mike Canevaro stated: “ShopTalk’s annual event is a major opportunity for retail stakeholders to come together to define the future of the industry. This year’s virtual event reflects the new landscape created by the COVID-19 pandemic, which has forced a digital transformation in the retail space. Loop is driving this transformation through its retail engagement, automated marketing, and AI-driven insights platform.”

This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/LoopInsights/forums/discussion

About Loop Insights:

Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace.

About ShopTalk Meetup:

More than 600 companies exhibit at and sponsor Shoptalk each year. This year’s Shoptalk Meetup is retail’s first digitally native event, offering a fun, productive way to connect online with the people you know and meet the people you don’t. Shoptalk Meetup features thousands of industry stakeholders available to share ideas and develop collaborative partnerships. The event includes both 15-minute meetings and 55-minute table discussions for high-priority connections in a friendly and open environment.

For more information, please contact:
Loop Insights Inc.LOOP Website : www.loopinsights.ai 
Rob Anson, CEOFacebook: @ LoopInsights 
T : +1 877-754-5336 Ext. 4Twitter: @ LoopInsights 
E : [email protected]LinkedIn: @LoopInsights 

Forward-Looking Statements/Information:  

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.